This analysis examined use of FDG PET-CT for people diagnosed with lung cancer in Te Manawa Taki Midland over 2011–2021. The investigators identified cases from the Midland Lung Cancer Register and the New Zealand Cancer Registry, then linked those records to the National Non-Admitted Patient Collection to determine PET‑CT receipt. Simple counts showed 613 patients with stage I disease, 300 with stage II, and 3,722 with stages III–IV. A substantial majority of early-stage patients underwent PET‑CT: 75% of stage I and 68.3% of stage II had the scan. Imaging use rose over time, the authors reported, indicating expanding adoption of PET‑CT across the study period. The source did not provide monthly or yearly rates in the abstract; therefore, detailed time-trend figures are not available here.
The study team used logistic regression to estimate odds ratios for receiving PET‑CT. Models adjusted for age, gender, ethnicity, year of diagnosis, socio-economic status, cancer stage, cell type, ECOG status and comorbidities. Patients aged 80 years and older were less likely to receive PET‑CT. Frailty, captured as ECOG 2 or greater, also reduced the likelihood of imaging. Those with stage II–IV disease were less likely to be scanned than patients with early-stage disease. The authors reported an ethnic disparity: Māori patients were less likely to undergo PET‑CT compared with non-Māori. Conversely, gender, socio-economic status and comorbidity burden did not show an influence on PET‑CT use in the adjusted models, according to the abstract. The source did not report numerical odds ratios or confidence intervals in the abstract text, so exact effect sizes are not reproduced here.
The authors concluded that PET‑CT is standard of care for patients with early-stage lung cancer who are suitable for curative treatment. Yet the analysis identified inequitable access: Māori patients were less likely to receive PET‑CT. That disparity persisted after adjustment for the clinical and demographic variables listed. The study did not report causal mechanisms for the ethnic difference in PET‑CT receipt in the abstract. Specific corrective measures were likewise not reported by the source. These gaps leave open important system-level and patient-level questions: what logistical, referral, cultural, or institutional factors are driving lower PET‑CT use among Māori in this region? The abstract makes clear that addressing this disparity is a stated priority.
The investigators drew on registry-based case ascertainment linked to national non-admitted patient data, which strengthens capture of imaging events that occurred outside inpatient records. The 2011–2021 timeframe allowed assessment of temporal uptake. The study team adjusted for several relevant covariates in multivariable models, including stage, ECOG status and socio-economic status.
Limitations reported in the abstract are limited. The source did not provide detailed numerical outputs, confidence intervals, or year-by-year trends in the abstract; those elements may appear in the full text but were not reported in the abstract. The authors did not report reasons for lower PET‑CT use among patients aged 80+, among frail patients, or among Māori—causal contributors were not identified in the abstract. The study also did not report whether access barriers were due to referral patterns, patient choice, capacity constraints, geographic distance, or other system-level factors. Finally, while the abstract states that gender, socio-economic status and comorbidities did not influence PET‑CT use, the exact definitions and categorizations for those variables were not described in the abstract.
Unanswered questions that remain, based on what the authors reported, include: what mechanisms explain the lower PET‑CT uptake for Māori, and what interventions would effectively close that gap? How much of the observed lower imaging rate in older and frail patients reflects appropriate clinical decision-making versus unequal access to staging investigations? The source indicates the disparity "needs to be addressed," but did not specify remedial strategies or report intervention data in the abstract. Future reporting or further analysis will need to supply effect estimates, confidence intervals and a breakdown of temporal trends to inform policy or service changes.
The study provides registry-linked evidence that PET‑CT use increased over the decade and that early-stage lung cancer patients frequently received PET‑CT, yet it also identifies persistent inequities in who receives that staging scan. The clinical and policy priority stated by the authors is to address lower access among Māori; the abstract does not report targeted solutions or causal analyses to explain the discrepancy.